◆ NeutralABTGKOSABBVALC
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool·
Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott trades at a lower valuation multiple but faces integration challenges and legal risks, while Glaukos shows rapid 32% revenue growth but remains unprofitable and dependent on a single manufacturing location.
Read Full Article at The Motley Fool →